# Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

> **NCT00728078** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 200 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cancer

## Interventions

- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00728078
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-07
- **Primary completion:** 2009-07
- **Final completion:** 2011-07
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2009-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00728078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00728078, "Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00728078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*